Bolt Biotherapeutics reported a net loss of $19.5 million for the nine months ended September 30, 2026, a significant reduction from the $26.7 million loss in the prior year period. The company recently acquired Prana Therapies, Inc. to pivot its focus toward the INSPIRE platform for multispecific antibodies while completing Phase 1/2 trials for BDC-4182.
Bolt Biotherapeutics reported Q3 2026 financial results and provided a business update following its acquisition of Prana Therapies and a concurrent $120 million private placement. The company is shifting its primary focus to the INSPIRE-built pipeline, specifically the Phase 2 development of PRA-216 for inflammatory indications, with a cash runway extending into 2028.
“Completing the Prana acquisition marks an important transformation for Bolt. With a strong balance sheet, an advanced clinical program and a differentiated platform, we believe we are well positioned to execute against the important milestones ahead.”
Willie Quinn, President and Chief Executive Officer
“The transaction and financing provide us with the capital and public-company foundation to advance PRA-216 and the broader INSPIRE pipeline through what we believe will be an exciting and highly data-rich period ahead.”
Bolt Biotherapeutics Insider Coastlands Capital LP Buys $319K of Stock
Coastlands Capital LP bought 50,000 shares of Bolt Biotherapeutics, Inc. at $6.38 a share, worth $319K in total on Nov 9, 2026. Shares held after the trade: 462,416 (+12.1%).
Bolt Biotherapeutics M&A Deal with Prana Therapies, Inc.
Bolt Biotherapeutics acquired Prana Therapies in a stock-for-stock reverse merger, issuing common and Series D preferred stock to Prana shareholders. Following the merger and a concurrent $120 million private placement, former Prana equityholders will own approximately 51.7% of the combined company. The transaction shifts Bolt's focus to Prana's INSPIRE platform and its lead bispecific antibody candidate, PRA-216, for inflammatory diseases.